Contrasting Monosymptomatic Patients with Hallucinations and Delusions in First-Episode Psychosis Patients: A Five-Year Longitudinal Follow-Up StudyEvensen J.a, b · Røssberg J.I.a, b · Haahr U.h · ten Velden Hegelstad W.e, f · Joa I.e, f · Johannessen J.O.e, f · Langeveld H.e, f · Larsen T.K.e, f · Melle I.a, b · Opjordsmoen S.a, b · Rund B.R.d · Simonsen E.h · Sundet K.d · Vaglum P.c · Friis S.a, b · McGlashan T.g
aDivision of Psychiatry, Oslo University Hospital, bInstitute of Psychiatry, cDepartment of Behavioral Sciences in Medicine and dInstitute of Psychology, University of Oslo, Oslo, eRegional Centre for Clinical Research in Psychosis, Psychiatric Clinic, Stavanger University Hospital, Stavanger, and fInstitute of Psychiatry, University of Bergen, Bergen, Norway; gDepartment of Psychiatry, Yale University School of Medicine, Yale Psychiatric Research at Congress Place, New Haven, Conn., USA; hRoskilde Psychiatric University Hospital Fjorden, Roskilde, Denmark
Julie Horgen Evensen
Psychiatric Division, Oslo University Hospital, Ullevaal
NO–0407 Oslo (Norway)
Tel. +47 99 41 07 52, Fax +47 22 11 84 23
Do you have an account?
Background: The main aim of this study was to identify subgroups of patients characterized by having hallucinations only or delusions only and to examine whether these groups differed with regard to demographic characteristics, clinical characteristics and outcome factors, including suicidality. Methods: Out of 301 consecutively admitted patients with first-episode psychosis, individuals with delusions only (D) and hallucinations only (H) were identified based on Positive and Negative Syndrome Scale (PANSS) items P1 (delusions) and P3 (hallucinations) scores at baseline and through 4 follow-up interviews over 5 years. The subgroups were compared with regard to demographic data, premorbid functioning, duration of untreated psychosis, clinical variables, time to remission and suicidality. Results: Two groups of patients were identified; H (n = 16) and D (n = 106). 179 patients experienced both hallucinations and delusions (dual symptom group). The H group was significantly younger, had a longer duration of untreated psychosis, poorer premorbid function and better insight than the D group. Notably, the H group scored higher on measures of suicidality, and at 5 years follow-up a significantly higher proportion of patients was lost to suicide in this group. The dual symptom group was closer to the D group on significant parameters, including suicidality and suicide rate. Conclusions: Patients with hallucinations only can be separated from patients with delusions only and the subgroups differ with regard to demographical data, clinical variables and notably with regard to suicidality. These findings suggest distinctions in the underlying biological and psychological processes involved in hallucinations and in delusions.
© 2011 S. Karger AG, Basel
- Allardyce J, Suppes T, Van Os J: Dimensions and the psychosis phenotype. Int J Methods Psychiatr Res 2007;16:34–40.
- Dutta R, Greene T, Addington J, McKenzie K, Phillips M, Murray RM: Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis. Schizophr Bull 2007;33:868–876.
- Craddock N, O’Donovan MC, Owen MJ: Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or ‘schizoaffective’) psychoses. Schizophr Bull 2009;35:482–490.
- Verhoeven WM, Tuinier S: Clinical perspectives on the genetics of schizophrenia: a bottom-up orientation. Neurotox Res 2008;14:141–150.
- Munro A: The classification of delusional disorders. Psychiatr Clin North Am 1995;18:199–212.
- Opjordsmoen S: DeIusional disorders I. Comparative long-term outcome. Acta Psychiatr Scand 1989;80:603–612.
- Opjordsmoen S: Delusional disorders. II. Predictor analysis of long-term outcome. Acta Psychiatr Scand 1989;80:613–619.
- Sommer IE, Daalman K, Rietkerk T, Diederen KM, Bakker S, Wijkstra J, Boks MP: Healthy individuals with auditory verbal hallucinations; who are they? Psychiatric assessments of a selected sample of 103 subjects. Schizophr Bull 2010;36:633–641.
- Honig A, Romme MA, Ensink BJ, Escher SD, Pennings MH, deVries, MW: Auditory hallucinations: a comparison between patients and nonpatients. J Nerv Ment Dis 1998;186:646–651.
- Mauri MC, Valli I, Ferrari VM, Regispani F, Cerveri G, Invernizzi G: Hallucinatory disorder: preliminary data for a clinical diagnostic proposal. Cogn Neuropsychiatry 2006;11:480–492.
- Mauri MC, Gaietta M, Dragogna F, Valli I, Cerveri G, Marotta G: Hallucinatory disorder, an original clinical picture? Clinical and imaging data. Prog Neuropsychopharmacol Biol Psychiatry 2008;15:523–530.
- Drake RJ, Dunn G, Tarrier N, Haddock G, Haley C, Lewis S: The evolution of symptoms in the early course of non-affective psychosis. Schizophr Res 2003;63:171–179.
- Harrow M, Jobe TH: How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophr Bull 2010;36:192–204.
- Grunebaum F, Oquendo MA, Harkavy-Friedman JM, Ellis SP, Li S, Haas GL, Malone KM, Mann JJ: Delusions and suicidality. Am J Psychiatry 2001;158:742–747.
- Fialko L, Freeman D, Bebbington PE, Kuipers E, Garety PA, Dunn G, Fowler D: Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. Acta Psychiatr Scand 2006;114:177–186.
- Kaplan KJ, Harrow M: Positive and negative symptoms as risk factors for later suicidal activity in schizophrenics versus depressives. Suicide Life Threat Behav 1996;26:105–121.
- Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlaeger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M: Suicidal behaviour and mortality in first-episode psychosis: the OPUS trial. Br J Psychiatry Suppl 2007;51:140–146.
- Larsen TK, McGlashan TH, Johannessen JO, Friis S, Guldberg C, Haahr U, Horneland M, Melle I, Moe LC, Opjordsmoen S, Simonsen E, Vaglum P: Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. Am J Psychiatry 2001;158:1917–1919.
- Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan TH: Reducing the duration of untreated first-episode psychosis. Arch Gen Psychiatry 2004;61:143–150.
- Friis S, Melle I, Larsen TK, Haahr U, Johannessen JO, Simonsen E, Opjordsmoen S, Vaglum P, McGlashan TH: Does duration of untreated psychosis bias study samples of first-episode psychosis? Acta Psychiatr Scand 2004;110:286–291.
- Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 1992;49:624–629.
- Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
- Bentsen H, Munkvold OG, Notland TH, Boye B, Bjoerge H, Lersbryggen AB, Oskarsson KH, Berg-Larsen R, Malt UF: The interrater reliability of the Positive and Negative Syndrome Scale (PANSS). Int J Methods Psychiatr Res 1996;6:227–235.
- Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766–771.
- Strauss JS, Carpenter WT: The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch Gen Psychiatry 1974;31:37–42.
- Lehman AF: A quality of life interview for the chronically mentally ill. Eval Program Plann 1988;11:51–62.
- Larsen TK, Friis S, Haahr U, Johannessen JO, Melle I, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PV, McGlashan TH: Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. Br J Psychiatry 2004;185:108–115.
- Friis S, Larsen TK, Melle I, Opjordsmoen S, Johannessen JO, Haahr U, Simonsen E, Rund BR, Vaglum P, McGlashan T, Nordic Association for Psychiatric Epidemiology: Methodological pitfalls in early detection studies – the NAPE Lecture 2002. Acta Psychiatr Scand 2003;107:3–9.
- Opjordsmoen S, Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Simonsen E, Rund BR, Vaglum P, McGlashan TH: Stability of medication in early psychosis: a comparison between second generation and low-dose first generation antipsychotics. Early Interv Psychiatry 2009;3:58–65.
Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, Krausz M, Lester D, Meltzer HY, Modestin J, Montross LP, Mortensen PB, Munk-Jørgensen P, Nielsen J, Nordentoft M, Saarinen PI, Zisook S, Wilson ST, Tatarelli R: Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007;16:6–10.
- Schwartz RC: Insight and suicidality in schizophrenia: a replication study. J Nerv Ment Dis 2000;188:235–237.
- Bourgeois M, Swendsen J, Young F, Amador X, Pini S, Cassano GB, Lindenmayer JP, Hsu C, Alphs L, Meltzer HY, InterSePT Study Group: Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry 2004;161:1494–1496.
- Crumlish N, Whitty P, Kamali M, Clarke M, Browne S, McTigue O, Lane A, Kinsella A, Larkin C, O’Callaghan E: Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand 2005;112:449–455.
- Engh JA, Friis S, Birkenaes AB, Jónsdóttir H, Klungsøyr O, Ringen PA, Simonsen C, Vaskinn A, Opjordsmoen S, Andreassen OA: Delusions are associated with poor cognitive insight in schizophrenia. Schizophr Bull 2010;36:830–835.
- Engh JA, Friis S, Birkenaes AB, Jonsdottir H, Ringen PA, Ruud T, Sundet KS, Opjordsmoen S, Andreeassen OA: Measuring cognitive insight in schizophrenia and bipolar disorder: a comparative study. BMC Psychiatry 2007;7:71.
- Jónsdóttir H, Engh JA, Friis S, Birkenaes A, Ringen PA, Vaskinn A, Sundet K, Opjordsmoen S, Andreassen OA: Measurement of insight in patients with bipolar disorder: are self-rated scales developed for patients with schizophrenia applicable? J Nerv Ment Dis 2008;196:333–335.
- Raffard S, Bayard S, Capdevielle D, Garcia F, Boulenger JP, Gely-Nargeot MC: Lack of insight in schizophrenia: a review. Encephale 2008;34:511–516.
- Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan T: Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 2006;163:800–804.
- Clarke M, Whitty P, Browne S, Mc Tigue O, Kinsella A, Waddington JL, Larkin C, O’Callaghan E: Suicidality in first episode psychosis. Schizophr Res 2006;86:221–225.
- Nordentoft M, Jeppesen P, Abel M, Kassow P, Petersen L, Thorup A, Krarup G, Hemmingsen R: OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 2002;43:98–106.
- Westermeyer JF, Harrow M, Marengo JT: Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J Nerv Ment Dis 1991;179:259–266.
- Aleman A, Agrawal N, Morgan KD, David AS: Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry 2006;189:204–212.
- Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan TH: Course and predictors of suicidality over the first two years of treatment in first episode psychosis. Arch Suicide Res 2010;14:158–170.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.